WallStSmart

Coca-Cola European Partners PLC (CCEP)vsWaters Corporation (WAT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Coca-Cola European Partners PLC generates 560% more annual revenue ($20.90B vs $3.17B). WAT leads profitability with a 20.3% profit margin vs 9.3%. WAT appears more attractively valued with a PEG of 1.25. WAT earns a higher WallStSmart Score of 60/100 (C).

CCEP

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 6.5Value: 7.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.55

WAT

Buy

60

out of 100

Grade: C

Growth: 4.0Profit: 9.0Value: 7.3Quality: 6.8
Piotroski: 4/9Altman Z: 4.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCEPUndervalued (+57.7%)

Margin of Safety

+57.7%

Fair Value

$230.72

Current Price

$93.23

$137.49 discount

UndervaluedFair: $230.72Overvalued
WATSignificantly Overvalued (-349.9%)

Margin of Safety

-349.9%

Fair Value

$73.17

Current Price

$302.32

$229.15 premium

UndervaluedFair: $73.17Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEP3 strengths · Avg: 9.0/10
EPS GrowthGrowth
68.3%10/10

Earnings expanding 68.3% YoY

Return on EquityProfitability
22.9%9/10

Every $100 of equity generates 23 in profit

Free Cash FlowQuality
$1.51B8/10

Generating 1.5B in free cash flow

WAT4 strengths · Avg: 9.5/10
Operating MarginProfitability
33.8%10/10

Strong operational efficiency at 33.8%

Altman Z-ScoreHealth
4.9210/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
29.3%9/10

Every $100 of equity generates 29 in profit

Profit MarginProfitability
20.3%9/10

Keeps 20 of every $100 in revenue as profit

Areas to Watch

CCEP4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.2%4/10

0.2% revenue growth

Altman Z-ScoreHealth
1.554/10

Distress zone — elevated risk

Debt/EquityHealth
1.503/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

WAT2 concerns · Avg: 3.0/10
P/E RatioValuation
28.1x4/10

Moderate valuation

EPS GrowthGrowth
-3.1%2/10

Earnings declined 3.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEP

The strongest argument for CCEP centers on EPS Growth, Return on Equity, Free Cash Flow.

Bull Case : WAT

The strongest argument for WAT centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 20.3% and operating margin at 33.8%. PEG of 1.25 suggests the stock is reasonably priced for its growth.

Bear Case : CCEP

The primary concerns for CCEP are Revenue Growth, Altman Z-Score, Debt/Equity.

Bear Case : WAT

The primary concerns for WAT are P/E Ratio, EPS Growth.

Key Dynamics to Monitor

CCEP profiles as a value stock while WAT is a mature play — different risk/reward profiles.

WAT carries more volatility with a beta of 1.20 — expect wider price swings.

WAT is growing revenue faster at 6.8% — sustainability is the question.

CCEP generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

WAT scores higher overall (60/100 vs 59/100), backed by strong 20.3% margins. CCEP offers better value entry with a 57.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Coca-Cola European Partners PLC

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Coca-Cola Europacific Partners PLC produces, distributes and sells a variety of ready-to-drink non-alcoholic beverages. The company is headquartered in Uxbridge, the United Kingdom.

Visit Website →

Waters Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.

Want to dig deeper into these stocks?